MOBERG DERMA INITIATES NEW STUDY OF MOB-015
Moberg Derma AB (OMX: MOB) today announces that it has received the final results from a phase II study of MOB-015 in patients with onychomycosis. The clinical efficacy was unsatisfactory, and the company has therefore decided to initiate a new study with an improved formulation.Based on the final results of the completed study, the company reiterates the assessment announced already in connection with a previous analysis of interim data; that the studied formulation of MOB-015 is not efficacious enough to justify further development. The study has provided valuable information that has